SCHEMBL4526253

SCHEMBL4526253

CCOC(=O)C(Cc1cnc2ccccc2n1)NC(C)=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.67
CYP2C9 P11712 1/20 0.67
HIF1A Q16665 1/20 0.67
ALDH1A1 P00352 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
KDM4E B2RXH2 2/20 0.47
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CASP3 P42574 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
TACR1 P25103 3/20 0.44
MAPT P10636 2/20 0.41
ELANE P08246 1/20 0.41
ABCB1 P08183 1/20 0.41
HTT P42858 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4523137 0.85 CYP1A2 (0.52) CYP1A2CYP2C9HIF1AALDH1A1SMN1; SMN2
SCHEMBL2299694 0.84 TACR1 (0.48) CYP1A2CYP2C9HIF1AALDH1A1SMN1; SMN2
SCHEMBL15599302 0.81 CYP1A2 (1.00) CYP1A2CYP2C9HIF1AALDH1A1SMN1; SMN2
SCHEMBL29903072 0.80 CYP1A2 (0.60) CYP1A2CYP2C9HIF1AALDH1A1SMN1; SMN2
SCHEMBL242241 0.74 TACR1 (0.71) CYP2C9ALDH1A1RAB9ATACR1TP53
SCHEMBL242242 0.74 TACR1 (0.71) CYP2C9ALDH1A1RAB9ATACR1TP53
SCHEMBL25412903 0.73 CYP1A2 (0.64) CYP1A2CYP2C9HIF1AALDH1A1SMN1; SMN2
Acetic Acid SCHEMBL27445733 0.73 TACR1 (0.69) CYP2C9ALDH1A1RAB9ATACR1TP53
SCHEMBL22775670 0.73 NLRP3 (0.41) CYP1A2CYP2C9HIF1ATACR1ACACB
SCHEMBL29702242 0.73 NLRP3 (0.41) CYP1A2CYP2C9HIF1ATACR1ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080263-A1 Method for producing ss-heteroaryl-alpha-alanine compounds using 2-amino-2-(heteroarylmethyl) carboxylic acid compounds CHIRACON GMBH (DE) 2005-04-14 US claimed
US-7626022-B2 Racemic mixtures; oxidation; cyclization; crystallization CHIRACON GMBH (DE) 2009-12-01 US disclosed
US-20050080263-A1 Method for producing ss-heteroaryl-alpha-alanine compounds using 2-amino-2-(heteroarylmethyl) carboxylic acid compounds CHIRACON GMBH (DE) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080263-A1 Method for producing ss-heteroaryl-alpha-alanine compounds using 2-amino-2-(heteroarylmethyl) carboxylic acid compounds AAAS, ASNS, AADAT CYP1A2 95/4885CYP2C9 120/4885HIF1A 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.